It's the latest evidence of rising spending in the drug discount program as regulators attempt to tamp down on growth in 340B.

A Florida hospital is suing Eli Lilly and Co. after the Indianapolis-based drugmaker moved to restrict some health systems’ access to a federal drug discount program intended for safety-net hospitals ...

AHA responds to Information Collection Request about the Health Resources and Services Administration’s proposed 340B Rebate Model Program.

Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% ...

Hospital drug markups are in the crosshairs as a new proposal targets 340B facilities where a $700 prostate cancer treatment ...

The 340B fights of 2026 are being waged as disputes over fairness and intent. Underneath, they are disputes over data.

In recent weeks, two competing visions have emerged to legislatively modernize the federal 340B drug discount program (“340B Program”).

Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% ...

The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient ...

Ten medications accounted for about 28.6% of the $100 billion in 340B outpatient drug purchases in 2025, according to new data from HRSA released July 13. The figure comes as 340B purchases hit a ...

If the road to hell is paved with good intentions, Washington has turned federal prescription drug policy into an eight-lane ...

Institutions that are not genuinely serving the underserved should not collect 340B discounts, and the loopholes that reward ...